These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 27644594)

  • 1. Predicting toxicities in humans by nonclinical safety testing: an update with particular reference to anticancer compounds.
    Ahuja V; Bokan S; Sharma S
    Drug Discov Today; 2017 Jan; 22(1):127-132. PubMed ID: 27644594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody Drug Conjugates: Nonclinical Safety Considerations.
    Hinrichs MJ; Dixit R
    AAPS J; 2015 Sep; 17(5):1055-64. PubMed ID: 26024656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of animal models of human disease for nonclinical safety assessment of novel pharmaceuticals.
    Morgan SJ; Elangbam CS; Berens S; Janovitz E; Vitsky A; Zabka T; Conour L
    Toxicol Pathol; 2013; 41(3):508-18. PubMed ID: 22968286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentials and limitations of nonclinical safety assessment for predicting clinical adverse drug reactions: correlation analysis of 142 approved drugs in Japan.
    Tamaki C; Nagayama T; Hashiba M; Fujiyoshi M; Hizue M; Kodaira H; Nishida M; Suzuki K; Takashima Y; Ogino Y; Yasugi D; Yoneta Y; Hisada S; Ohkura T; Nakamura K
    J Toxicol Sci; 2013; 38(4):581-98. PubMed ID: 23824014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
    Lawrence CL; Pollard CE; Hammond TG; Valentin JP
    J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.
    Ponce R; Abad L; Amaravadi L; Gelzleichter T; Gore E; Green J; Gupta S; Herzyk D; Hurst C; Ivens IA; Kawabata T; Maier C; Mounho B; Rup B; Shankar G; Smith H; Thomas P; Wierda D
    Regul Toxicol Pharmacol; 2009 Jul; 54(2):164-82. PubMed ID: 19345250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicologic Pathology Forum: Current Status on the Use of Animal Models of Human Disease in the Pharmaceutical Industry in Japan in Nonclinical Safety Assessment-Opinion Paper.
    Tomohiro M; Okabe T; Kimura Y; Kinoshita K; Maeda M; Mitobe Y; Motoyama K; Yonezawa R; Sasaki S; Fujiwara M; Watanabe K
    Toxicol Pathol; 2019 Feb; 47(2):108-120. PubMed ID: 30636562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.
    Newell DR; Burtles SS; Fox BW; Jodrell DI; Connors TA
    Br J Cancer; 1999 Nov; 81(5):760-8. PubMed ID: 10555743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum chemical biomarkers of cardiac injury for nonclinical safety testing.
    Walker DB
    Toxicol Pathol; 2006; 34(1):94-104. PubMed ID: 16507550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
    Amacher DE
    Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zebrafish based assays for the assessment of cardiac, visual and gut function--potential safety screens for early drug discovery.
    Berghmans S; Butler P; Goldsmith P; Waldron G; Gardner I; Golder Z; Richards FM; Kimber G; Roach A; Alderton W; Fleming A
    J Pharmacol Toxicol Methods; 2008; 58(1):59-68. PubMed ID: 18585469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictivity/Translatability of Toxicities Observed in Nonclinical Toxicology Studies to Clinical Safety Outcomes in Drug Development: Case Examples.
    Stagg NJ; Ghantous HN; Roth R; Hastings KL
    Int J Toxicol; 2020; 39(2):141-150. PubMed ID: 31875744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonclinical Evaluations of Small-Molecule Oncology Drugs: Integration into Clinical Dose Optimization and Toxicity Management.
    Dambach DM; Simpson NE; Jones TW; Brennan RJ; Pazdur R; Palmby TR
    Clin Cancer Res; 2016 Jun; 22(11):2618-22. PubMed ID: 27250932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonclinical development of biopharmaceuticals.
    Baumann A
    Drug Discov Today; 2009 Dec; 14(23-24):1112-22. PubMed ID: 19853058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of juvenile toxicity.
    Barrow PC; Barbellion S; Stadler J
    Methods Mol Biol; 2011; 691():17-35. PubMed ID: 20972745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of preclinical toxicology studies for platinum anticancer drugs.
    Clark DL; Andrews PA; Smith DD; DeGeorge JJ; Justice RL; Beitz JG
    Clin Cancer Res; 1999 May; 5(5):1161-7. PubMed ID: 10353752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs in control samples in nonclinical safety studies: a reconsideration.
    Zimmer D
    Bioanalysis; 2016 May; 8(10):1003-7. PubMed ID: 27080047
    [No Abstract]   [Full Text] [Related]  

  • 19. Nonclinical Safety Testing of RNA Vaccines.
    Hager G
    Methods Mol Biol; 2017; 1499():253-272. PubMed ID: 27987155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Appropriate use of recovery groups in nonclinical toxicity studies: value in a science-driven case-by-case approach.
    Pandher K; Leach MW; Burns-Naas LA
    Vet Pathol; 2012 Mar; 49(2):357-61. PubMed ID: 21810619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.